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Tiivistelmä 
Tutkimuksen tausta ja tavoitteet: Keliakia on gluteenin laukaisema sairaus, jolle on 
tyypillistä autoimmuunivaste transglutaminaasi 2 (TG2)-entsyymiä kohtaan. Keliakiassa 
TG2-spesifiset plasmasolut erittävät immunoglobuliiniluokan (Ig) A autovasta-aineita TG2:ta 
vastaan. Näiden solujen on esitetty saavan alkunsa IgD- ja IgM-positiivisista B-soluista. B-
solujen on oletettu yleisesti kehittyvän imukeräsissä, jolle on tyypillistä Pax5-
transkriptiotekijän ja aktivaatio-indusoidun sytidiinideaminaasin (AID) ilmentäminen. 
Tuoreen hypoteesin mukaan TG2-spesifisten B-solujen kehitys saattaa kuitenkin tapahtua 
imukerästen ulkopuolella suoliston limakalvolla. Suurin osa keliakiapotilasmateriaalista 
koostuu ohutsuolibiopsinäytteistä. Ne sisältävät vähän imukeräsiä, mikä ei mahdollista B-
solujen kehityksen tutkimista. Imukeräsiä sisältävää imukudosta on kuitenkin runsaasti 
duodenaalisessa bulbuksessa. Työn tarkoituksena oli tutkia, onko keliakiapotilaiden TG2-
spesifisiä B-soluja imukeräsissä vai niiden ulkopuolella ainutlaatuisen suuren, keliaakikoista 
ja terveistä kontrolleista kerätyn duodenaalisen bulbusbiopsinäytesarjan avulla. 
 
Tutkimusmenetelmät: Ensimmäisessä vaiheessa käytiin läpi 211 suomalaista ja 268 
romanialaista duodenaalista bulbusbiopsinäytettä, joista seulottiin imukudoksellisia 
imukeräsiä todennäköisimmin sisältävät näytteet, mukaan lukien eristetyt imukeräset (ILF) ja 
Peyerin levyt (PP). Toisessa vaiheessa TG2-spesifisiä B-soluja havainnointiin 
immunofluoresenssivärjäyksen avulla. Värjäysprotokollassa käytettiin biotinyloitua 
rekombinantti-TG2:ta laimennoksella 1:100 ja vasta-aineita IgA:ta, IgD:tä, IgM:ää, AID:tä ja 
Pax5:ttä vastaan kolokalisaation havaitsemiseksi. 
 
Tutkimustulokset: Kaikista 479 seulotusta näytteestä 14 % sisälsi ILF-rakenteellista 
imukudosta ja 2,7 % PP-rakenteellista imukudosta. Immunofluoresenssivärjäyksen 
optimoinnissa primäärivasta-ainelaimennoksiksi valittiin 1:25 IgD:lle ja IgM:lle, 1:100 
AID:lle ja 1:250 Pax5:lle. Lopulliseen värjäykseen valittiin neljä hoitamatonta 
keliaakikkonäytettä ja kolme kontrollinäytettä. Keliaakikoissa havaittiin yhteensä kolme TG2-
IgA-, neljä TG2-IgD- ja neljä TG2-AID-tuplapositiivista solua, jotka eivät olleet osana mitään 
tunnistettavaa imukudosta. TG2-IgM- ja TG2-Pax5-tuplapositiivisia soluja ei havaittu 
keliaakikoissa. Kahdessa kontrollissa havaittiin yksittäisiä IgD-, IgM- ja Pax5-positiivisia, 
TG2-spesifisiä B-soluja. 
 
Johtopäätökset: Keliakiapotilaiden duodenaalisista bulbusbiopsinäytteistä löydettiin 
yksittäisiä TG2-spesifisiä B-soluja, jotka ilmentivät IgD:tä tai AID:tä ja jotka eivät olleet 
osana mitään tunnistettavaa imukudosrakennetta. Tulosten mukaan duodenaalisen bulbuksen 
limakalvolla saattaa siis kehittyä pieni määrä TG2-spesifisiä soluja imukerästen ulkopuolella.  
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Abstract 
Background and aims: Coeliac disease (CD) is a gluten-induced disorder, which is 
characterized by an autoimmune response against enzyme transglutaminase 2 (TG2). In CD, 
TG2-specific plasma cells secrete immunoglobulin (Ig) class A autoantibodies against TG2. 
These cells are assumed to develop from IgD and IgM positive B cells. The common 
development of B cells is suggested to occur in lymphoid follicles and is characterized by the 
expression of transcription factor Pax5 and activation-induced cytidine deaminase (AID). 
However, a recent hypothesis suggests that the development of TG2-specific B cells may 
occur at extra-follicular sites of the intestinal mucosa. The majority of CD-patient material 
consists of small intestine biopsies, which are devoid of lymphoid follicles, and therefore is 
insufficient for studying the B cell differentiation. However, there is an abundance of 
lymphoid tissues that contain lymphoid follicles in the duodenal bulb. The aim of this thesis 
was to investigate whether CD-patient TG2-specific B cells exist in lymphoid follicles or at 
extra-follicular sites using a uniquely large collection of duodenal bulb biopsies from CD-
patients and healthy controls. 
 
Methods: The first phase was to screen 211 Finnish and 268 Romanian duodenal bulb 
biopsies to identify specimens most likely to contain lymphoid tissues with lymphoid 
follicles, including isolated lymphoid follicles (ILFs) and Peyer’s patches (PPs). The second 
phase was to detect TG2-specific B cells using immunofluorescence staining. The staining 
protocol consisted of biotinylated recombinant TG2 at a dilution of 1:100 and co-localization 
using antibodies against IgA, IgD, IgM, AID, and Pax5. 
 
Results: Out of all the 479 screened specimens, 14% contained structures resembling ILFs 
and 2.7% contained structures resembling PPs. The chosen primary antibody dilutions in the 
optimized immunofluorescence staining were 1:25 for IgD and IgM, 1:100 for AID, and 
1:250 for Pax5. Four specimens from untreated CD-patients and three specimens from non-
CD controls were chosen for the final staining. In CD-patients, a total of three TG2-IgA 
double positive cells, four TG2-IgD double positive cells, and four TG2-AID double positive 
cells were identified that were no part of any recognizable lymphoid tissue. No TG2-IgM or 
TG2-Pax5 double positive cells were detected in CD-patients. Single IgD, IgM, and Pax5 
positive TG2-specific B cells were detected in two controls. 
 
Conclusions: Single TG2-specific B cells expressing IgD or AID were identified that were no 
part of any recognizable lymphoid tissue structure in CD-patient duodenal bulb biopsies. 
Therefore, the results suggest that a low number of TG2-specific B cells may develop at 
extra-follicular sites in the duodenal bulb mucosa.  
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1 Introduction 
Coeliac disease (CD) is an autoimmune-mediated disorder induced by gluten in genetically 
susceptible individuals (Stamnaes and Sollid 2015). It affects approximately 1 in 100 people in 
Europe and the United States (Singh et al. 2018). The consumption of gluten induces an 
abnormal immune response coupled with gastrointestinal symptoms due to structural changes 
in the intestine (Lindfors et al. 2019). At the moment, the only treatment is gluten-free diet. 
Therefore, there is a significant need to study CD and find new treatment options. 
CD4
+
 T cells recognize gluten peptides deamidated by the enzyme transglutaminase 2 (TG2), 
which is located in the small intestine and various other organs (Nurminskaya and Belkin 
2012). It has been hypothesized that TG2 and deamidated gluten peptides form complexes, 
which allow gluten-reactive T cells to provide help to TG2-specific B cells (Mesin et al. 
2012). In CD, differentiated TG2-targeting B cells, known as TG2-specific plasma cells, 
produce anti-TG2 autoantibodies that are predominantly immunoglobulin (Ig) class A and 
present in serum and various tissues (Stamnaes and Sollid 2015). 
According to the current knowledge, the development of B cells takes place in lymphoid 
tissues, which contain lymphoid follicles (Mesin et al. 2012). In lymphoid follicles, early 
phase B cells express antigen-specific IgD and IgM on their surface, and upon encountering 
with an antigen, a differentiation to plasma cells occurs along with a class-switch to IgA (Di 
Niro et al. 2012). The diagnostic biopsies for CD are normally taken from the duodenum or 
jejunum, and generally do not contain lymphoid tissues with lymphoid follicles. Therefore, 
most of the CD-patient material is insufficient for studying B cell development in CD. 
There is an abundance of lymphoid tissues that contain lymphoid follicles in the duodenal 
bulb, which is a small area between the stomach and duodenum (See Figure 2). The CD-
researchers at the Tampere Center for Child Health Research have a uniquely large collection 
of frozen duodenal bulb biopsies from CD-patients and non-CD controls. Therefore, it is now 
possible for the first time to investigate the development of human TG2-specific B cells in 
this specific location. The aim of this thesis was to investigate if early phase TG2-specific B 
cells can be found from the duodenal bulb using immunofluorescence staining. In addition to 
IgD and IgM, early phase B cells express transcription factor Pax5 and activation-induced 
cytidine deaminase, which were observed with immunofluorescence by using corresponding 
antibodies. The focus of this thesis is the immunology of CD, CD-specific antibodies, and the 
development of CD-specific B cells.  
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2 Literature Review 
2.1 Overview of coeliac disease 
Coeliac disease (CD) is a chronic autoimmune-mediated enteropathy elicited by dietary 
gluten protein in genetically predisposed individuals. CD affects approximately 1% of the 
populations of Europe and the United States, but the rate varies between countries (Singh et 
al. 2018). In CD, the ingestion of gluten present in wheat, rye, and barley induces an abnormal 
immune response, which eventually may lead to the development of crypt hyperplasia and 
villous atrophy in the small intestine, as well as chronic inflammation in the intestinal 
epithelium and lamina propria (LP; Stamnaes and Sollid 2015). The small-intestinal damage 
is paralleled by gastrointestinal symptoms, such as malabsorbtion, abdominal distention, and 
chronic diarrhea (Stamnaes and Sollid 2015). CD has also been associated with a variety of 
extra-intestinal manifestations, including skin disease dermatitis herpetiformis, hepatitis, 
osteoporosis, and infertility (Bonciani et al. 2012; Castillo et al. 2015; Khashan et al. 2010). 
The genetic susceptibility to CD is conferred by distinct major histocompatibility complex 
(MHC) class II alleles coding for human leukocyte antigen (HLA) molecules. Approximately 
90% of all CD-patients carry a HLA-DQ2 haplotype and almost all the reminder HLA-DQ8 
haplotype (Megiorni and Pizzuti 2012). At the population level, approximately 40% possess 
these alleles, but only a minority of these individuals acquires CD during their lifetime 
(Lindfors et al. 2019). CD is common in certain risk groups, including first-degree relatives 
and patients suffering from autoimmune diseases, such as type 1 diabetes mellitus (Lindfors et 
al. 2019). The prevalence of CD has increased over the last century, which has been suggested 
to be contributed by the hygiene-hypothesis (Lohi et al. 2007). The increased percentage of 
CD may also be explained by improved diagnostic methods, including serological tests and 
duodenal biopsies. Dietary and environmental factors, such as intestinal microbiota, have also 
been suggested to contribute to the CD progression (De Re et al. 2017). 
At present, the only effective treatment for CD is a life-long gluten-free diet (GFD) in which 
wheat, rye, and barley are excluded from diet. Strict GFD usually results in recovery of the 
gastrointestinal mucosa and alleviation of symptoms (Laurikka et al. 2016). Untreated CD is 
associated with decreased quality-of-life (Ukkola et al. 2011). Dietary treatment increases the 
quality-of-life, although it may not reach the level of the general population, possibly due to 
major dietary restrictions (Ukkola et al. 2011). Furthermore, despite GFD, symptoms may 
sometimes persist and the mucosal recovery may take years (Laurikka et al. 2016). 
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2.2 Immunology of coeliac disease 
Food antigens do not generally induce a systemic immune response, a phenomenon known as 
oral tolerance which is not well understood in humans (Stamnaes and Sollid 2015). However, 
it is known that there is a breakage of oral tolerance towards dietary gluten in CD (Stamnaes 
and Sollid 2015). The gluten induces innate and adaptive immune responses, and it has been 
suggested that both innate and adaptive immune responses are required for the development 
of full-blown CD (Stamnaes and Sollid 2015). Next, I will discuss the role of the intestinal 
immune system, duodenal bulb, antigens, and the induced immune responses in the 
pathogenesis of CD. 
2.2.1 Intestinal immune system 
Intestinal epithelium and mucosal layer provide mechanical and chemical protection by 
forming tight connections between intestinal epithelial cells, producing mucus, and secreting 
antimicrobial peptides (Konig et al. 2016; Spencer and Sollid 2016). CD3
+
 small-intestinal 
intraepithelial lymphocytes (IELs) are located in the intestinal epithelial cell layer and act as a 
protective mechanism by killing infected or damaged epithelial cells (Lindfors et al. 2019; 
Stamnaes and Sollid 2015). Approximately 75% of the IELs are composed of CD8
+
 T cells 
expressing T cell receptor (TCR) chains αβ+, 10% CD4+ T cells expressing TCRαβ+, and 15% 
either CD4
+
 or CD8
+
 T cells expressing TCRγδ+ (Cukrowska et al. 2017). CD8+ T cells 
recognize HLA-I-peptide complex, which activates a cell-mediated cytotoxic response, 
whereas CD4
+
 T cells recognize HLA-II-peptide complex, which in turns induces a humoral 
response (Megiorni and Pizzuti 2012). IELs also express both inhibitory and activating 
natural killer (NK) receptors (Lindfors et al. 2019). 
Primary intestinal immune response induction occurs in gut-associated lymphoid tissue 
(GALT), which is considered as its own immunological compartment, as it differs from the 
peripheral lymphoid system in several aspects, including the immediate juxtaposition of the 
mucosal epithelium and lymphoid tissue, and the specialized antigen uptake mechanisms 
(Mesin et al. 2012). GALT also maintains activated lymphocytes even in the absence of 
infection. GALT consists of aggregated lymphoid follicles, termed Peyer’s patches (PPs), 
isolated lymphoid follicles (ILFs), and diffuse lymphoid tissue (Mesin et al. 2012). All 
lymphoid tissue types consist of a three-dimensional framework of reticular fibers, reticular 
cells, and lymphocytes. PPs are organized structures composed of clustered lymphoid follicles 
and interfollicular CD4
+
 T cell zones (Knoop and Newberry 2012). Lymphoid follicles consist 
of developing B cells, including immature, CD19 B cell lineage differentiation marker 
4 
 
positive B cells that express IgD and IgM with antigen-specific B cell receptors (BCRs; 
Knoop and Newberry 2012). PPs are covered with microfold cells located in the follicle-
associated epithelium (FAE) of GALT and antigen-presenting cells (APCs) in the 
subepithelial layer, including CD11c
+
 dendritic cells (DCs; Knoop and Newberry 2012). In 
addition to PPs, more compactly structured ILFs have been recently discovered in humans 
(Moghaddami et al. 1998) and in mice (Hamada et al. 2002). ILFs contain a B cell 
composition similar to the lymphoid follicles of PPs, and they are covered with CD4
+
 T cells 
and APCs (Hamada et al. 2002; Knoop and Newberry 2012). However, unlike PPs which 
remain in mature state throughout life, ILFs range from immature cryptopatches to fully 
matured structures that contain compensatory mechanisms for humoral responses (Knoop and 
Newberry 2012). In contrast to the firmly structured PPs and ILFs, diffuse lymphoid tissue is 
a widely dispersed constituent of lymphatic organs and loosely aggregated cells in LP, 
particularly in the connective tissue underlining the small intestine (Cesta 2006). The 
structure and the cell composition of each lymphoid tissue type are illustrated in Figure 1. 
 
 
Figure 1. Cell composition of the lymphoid tissues in the small intestine. Peyer’s patches, 
isolated lymphoid follicles, and diffuse lymphoid tissue contain CD4
+
 T cells and immature 
CD19
+
 B cells expressing IgD and/or IgM on their surface. Peyer’s patches and isolated 
lymphoid follicles also contain CD11c
+
 dendritic cells (DCs). Immature B cells differentiate 
into plasma cells, which migrate to the intestinal lamina propria. Figure drawn according to 
Knoop and Newberry 2012. 
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2.2.2 Duodenal bulb 
Duodenal bulb is an approximately five centimeters long area between stomach and 
duodenum, as seen in Figure 2. It starts at the pylorus and ends at the gall bladder neck. It has 
a round shape and a smoother surface compared to the duodenum that has longer villi and 
other folded structures (http://duodenal.org/duodenal-bulb/; 21.9.2018). Duodenal bulb 
participates in the food digestion process along with the rest of the intestinal tract. 
CD-related lesions, such as crypt hyperplasia and villous atrophy, are generally investigated 
in the distal duodenum and proximal jejunum to confirm the diagnosis for CD (Bonamico et 
al. 2008; Vogelsang et al. 2001). However, according to Bonamico and co-workers, these 
characteristic lesions can also be found in duodenal bulb biopsies (Bonamico et al. 2008). 
They also observed that sometimes the duodenal bulb mucosa was affected, while the rest of 
the intestinal region showed no lesions. According to McCarty and co-workers, biopsy and 
histological examination of duodenal bulb in addition to the distal duodenum increases the 
diagnostic yield of CD (McCarty et al. 2018). This could be explained by the high amount of 
lymphoid tissues in the duodenal bulb and that the bulb is the first one to be reached by gluten 
(Bonamico et al. 2008; McCarty et al. 2018; Stoven et al. 2016; Vogelsang et al. 2001). 
Despite these results, the reliability of duodenal bulb biopsies in diagnosis of CD is uncertain 
due to common abnormal histological findings in the duodenal bulb area (Stoven et al. 2016; 
Taavela et al. 2016). Furthermore, the quality of the biopsy specimens from duodenal bulb 
may vary considerably (Lindfors et al. 2019; Taavela et al. 2016). 
 
Figure 2. Schematic structure of the gastrointestinal tract from stomach to duodenum. 
The location of the duodenal bulb is marked with an arrow and a circle. 
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2.2.3 Gluten and transglutaminase 2 as antigens in coeliac disease 
Gluten is a storage protein found in wheat, rye, and barley. It is composed of insoluble 
prolamine polypeptides, namely gliadins and glutenins in wheat, secalin in rye, and hordein in 
barley (Castillo et al. 2015). Gluten is highly resistant to proteolytic degradation in the 
gastrointestinal system due to high proline residue content, resulting in generation of 
relatively long, immunogenic gluten-derived peptides, which can be exposed to intestinal 
immune cells (Lindfors et al. 2019). Gliadin fractions are classified into α-, β-, δ-, and ω-types 
based on their primary structure (Stoven et al. 2012). The α-type is considered most harmful 
for CD-patients, and it can elicit both innate and adaptive immune responses (Stamnaes and 
Sollid 2015; Stoven et al. 2012). Gluten-derived peptides can pass through the intestinal 
epithelium into LP using either transcellular or paracellular transport (Lindfors et al. 2019). 
The exact transportation mechanism is not known, although several suggested models exist, 
such as a tight junction disassembly induced by gluten, which increases paracellular 
permability of the epithelium (Clemente et al. 2003), and transportation using different 
intracellular trafficking routes (Barone et al. 2010). 
Transglutaminase 2 (TG2) is a multifunctional Ca
2+
-dependent enzyme member of the 
transglutaminase family. TG2 catalyzes post-translational modification of proteins by 
transamidation or deamidation, and in addition acts as a GTPase/ATPase, protein disulfide 
isomerase, and protein kinase (Nurminskaya and Belkin 2012). It is ubiquitously expressed in 
both the intracellular and the extracellular spaces of various types of tissues and organs, 
although it is only enzymatically active in the extracellular space for reasons that are not 
understood (De Re et al. 2017). It is believed that TG2 is associated in the small intestine with 
fibronectin in the basement membrane supporting the epithelial cell layer (Stamnaes and 
Sollid 2015). TG2 is involved in many cellular processes, including adhesion, migration, 
growth, apoptosis, and differentiation (De Re et al. 2017; Meresse et al. 2012; Nurminskaya 
and Belkin 2012). It contributes to various physiological responses and pathological states, 
including wound healing, inflammation, autoimmunity, and tumor growth (De Re et al. 2017; 
Nurminskaya and Belkin 2012). 
TG2 has an undisputed role in CD due to its capability to modify gluten post-translationally 
by deamidation, which changes glutamine residues in specific glutamine-proline rich motifs 
into negatively charged glutamic acid residues (Molberg et al. 1998). These modified peptides 
are known as deamidated gliadin peptides (DGPs). DGPs contain epitopes with an increased 
binding affinity to either HLA-DQ2 or HLA-DQ8, but not to other MHC class II molecules 
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(Stamnaes and Sollid 2015). These HLA-DQ molecules on APCs present DGPs to CD4
+
 T 
cells, which is crucial for the pathogenesis of CD (Bodd et al. 2012; Iversen et al. 2015). TG2 
can also cross-link proteins by forming an isopeptide bond between glutamine and lysine. The 
cross-linking of TG2 and DGPs forms TG2-DGP complexes that would allow DGP-specific 
CD4
+
 T cells to present TG2 to TG2-specific B cells (Iversen et al. 2015). However, the 
mechanism by which TG2 becomes autoantigen in CD is not yet completely understood (De 
Re et al. 2017; Stamnaes and Sollid 2015). 
2.2.4 Innate immune response in coeliac disease 
Innate immune response in CD is suggested to be mediated by cytokine interleukin (IL)-15, 
which is secreted by intestinal epithelial cells and DCs after stimulation by gliadin peptides 
and other antigens present in wheat (Iacomino et al. 2016; Lindfors et al. 2019). In CD, the 
number of cells secreting IL-15 is increased in both the LP and the intestinal epithelium 
(Iacomino et al. 2016). IL-15 participates in the activation and selective expansion of IELs, 
particularly cells expressing TCRγδ+ (Meresse et al. 2012). The density of IELs is elevated in 
CD, and they participate in the intestinal epithelial damage by killing epithelial cells, possibly 
due to the loss of inhibitory natural killer cell group (NKG) 2A receptors and up-regulation of 
activating NKG2C receptors (Lindfors et al. 2019; Meresse et al. 2012; Stamnaes and Sollid 
2015). IL-15 also increases the expression of NKG2D receptor and its epithelial ligand, major 
histocompatibility class I polypeptide-related sequence A (MICA), which is located on 
intestinal epithelial cells (Stamnaes and Sollid 2015). The interaction between NKG2D and 
MICA induces cytotoxic response in CD8
+
 TCRαβ+ IELs at an increased level, which leads to 
barrier dysfunction and leaking of the epithelium (Cukrowska et al. 2017; Meresse et al. 
2012). Other secreted cytokines associated with innate immune response include type I 
interferons and IL-18 (Lindfors et al. 2019).  
The immunoregulatory system has an important role in downregulating the inflammation in 
the early phase of CD. The number of CD4
+
CD25
+
 regulatory T (Treg) cells is increased 
already in the early phase of CD, and IL-15 is not able to impair the production of anti-
inflammatory interferon (IFN)-γ and transforming growth factor β of these cells (Borrelli et 
al. 2013; De Re et al. 2017). However, in active CD, IL-15 appears to increase the resistance 
of T cells against the suppression of Treg cells (Hmida et al. 2012). This may be explained by 
the higher amount of IL-15 receptor expression on Treg cells in active CD (Borrelli et al. 
2013). The basic mechanism of the innate immune response in CD is illustrated in Figure 3. 
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Figure 3. Innate immune response in coeliac disease. The response is initiated by gliadins 
and other antigens present in wheat. Dendritic cells recognize these molecules and secrete 
interleukin (IL)-15 along with the intestinal epithelial cells. IL-15 increases the expression of 
NKG2D receptors on intraepithelial lymphocytes (IELs), which recognize MICA on adjacent 
intestinal epithelial cells. NKG2D-MICA interactions are increased, leading to enhanced 
cytotoxic responses of IELs. In addition, IL-15 can inhibit the regulatory effects of regulatory 
T (Treg) cells. Figure drawn according to Lindfors et al. 2019 and Meresse et al. 2012. 
2.2.5 Adaptive immune response in coeliac disease 
Adaptive immune response in CD is hallmarked by CD4
+
 T cell and B cell responses and 
antibodies produced by CD-specific plasma cells. CD-specific adaptive immune response is 
induced by DGPs, which are thought to be recognized by HLA-DQ2/DQ8 molecules on the 
surface of different APCs, including microfold cells and CD11c
+
 DCs (Mesin et al. 2012; 
Stamnaes and Sollid 2015). Thereafter, DGP-presenting DCs and other APCs are assumed to 
migrate to GALT, where they induce the activation of immature CD4
+
 T cells (Meresse et al. 
2012). These DGP-reactive CD4
+
 T cells acquire a pro-inflammatory phenotype and are 
thought to provide help to TG2-targeting B cells to differentiate into plasma cells that produce 
autoantibodies against TG2. CD4
+
 T cells also recruit NK cells to further stimulate the 
destruction of the intestinal epithelial cells (Stamnaes and Sollid 2015). DGP-specific CD4
+
 T 
cells can form a pool of memory cells that may explain the fast response against gluten upon 
its reintroduction after GFD (Stamnaes and Sollid 2015). The innate immune cytokine, IL-15, 
also activates CD4
+
 T cells, which secrete pro-inflammatory cytokines, such as IFN-γ and IL-
21 (Stamnaes and Sollid 2015). IL-15 may also synergize with cytokines produced by CD4
+
 T 
cells that stimulates the expansion of cytotoxic CD8
+
 T cells (Meresse et al. 2012). IL-21 
stimulates CD4
+
 T cells to produce more IFN-γ and IL-15, and it has been suggested that IL-
21 connects innate and adaptive immune responses (Sarra et al. 2013). 
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There are many suggested models that depict the connection between B cells, T cells, and 
TG2-DGP complexes. These models are based on the ability of TG2-specific B cells to 
internalize and process TG2-DGP complexes and to release covalently linked DGP T cell 
epitopes for MHC class II presentation to T cells (Iversen et al. 2015; Stamnaes and Sollid 
2015). Therefore, B cells may contribute equally well to the activation of T cells and may act 
as APCs (Stamnaes and Sollid 2015). TG2-DGP complex can be formed via two ways: either 
by coupling to the active site cysteine via a thioester-bond or by coupling to surface exposed 
lysine residues via isopeptide bonds (Di Niro et al. 2012; Stamnaes and Sollid 2015). These 
covalently linked complexes are unusually stable but short-lived enzyme-substrate 
intermediates (Stamnaes and Sollid 2015). TG2 can also form TG2-multimers, which could 
also contain DGP T cell epitopes while retaining recognition by anti-TG2 autoantibodies 
(Stamnaes and Sollid 2015). The basic mechanism of the adaptive immune response in CD is 
illustrated in Figure 4. 
 
Figure 4. Adaptive immune response in coeliac disease. Gluten-derived peptides are 
transferred through the intestinal epithelial cell layer to the lamina propria, where their 
deamidation into deamidated gliadin peptides (DGPs) by transglutaminase 2 (TG2) is thought 
to occur. Dendritic cells and other antigen-presenting cells recognize DGP and present HLA-
DQ-bound DGP to CD4
+
 T cells, which recognize the molecule via their T cell receptors 
(TCRs). These DGP-specific CD4
+
 T cells possibly activate TG2-specific B cells with the 
help of TG2-DGP complexes. Activated B cells differentiate into TG2-specific plasma cells 
that produce autoantibodies against TG2. Activated CD4
+
 T cells also secrete pro-
inflammatory cytokines, including interferon (IFN)-γ and interleukin (IL)-21. Figure drawn 
according to Lindfors et al. 2019, Meresse et al. 2012, and Stamnaes and Sollid 2015. 
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2.3 Antibodies in coeliac disease 
Antibodies against TG2 and DGPs are a characteristic feature of CD, and they appear in very 
early phases of the disease, possibly months or years before any noticeable morphological 
changes in the small-intestinal mucosa (Di Niro et al. 2012; Kurppa et al. 2009; Lindfors et al. 
2019). CD-associated antibodies were first characterized in the 1970s as anti-reticulin 
antibodies, which bind to reticulin fibres of the endomysium in rodent connective tissue (Seah 
et al. 1971). In the 1980s, these antibodies were characterized as native gliadin antibodies and 
IgA endomysial antibodies (EmA) binding endomysium in the smooth muscle of the monkey 
esophagus (Chorzelski et al. 1983). The target of EmA was later identified as TG2 (Dieterich 
et al. 1997). Since then, CD-specific TG2-targeting serum autoantibodies have been used in 
the diagnostics of CD along with histological evaluation (Mesin et al. 2012). Anti-TG2 
autoantibodies are commonly measured by quantitative enzyme-linked immunosorbent assay 
(Collin et al. 2005; Mesin et al. 2012). Human umbilical cord is used in testing for EmAs 
from CD-patients’ sera (Ladinser et al. 1994). Other diagnostic methods have also been 
developed, such as a rapid point-of care test for TG2-autoantibodies (Korponay-Szabo et al. 
2005; Lindfors et al. 2019). CD-specific anti-TG2 autoantibodies can be observed in 
cryosected small intestine biopsies using either direct or indirect immunofluorescence. Next, I 
will discuss the different antibodies associated with CD and their potential role in the disease. 
2.3.1 Antibodies associated with coeliac disease 
Anti-DGP antibodies are predominantly IgA and IgG, while anti-TG2 autoantibodies are 
predominantly IgA (Di Niro et al. 2012; Giersiepen et al. 2012; Iversen et al. 2015). Patients 
who have humoral IgA deficiency produce IgG or IgM autoantibodies against TG2 (Meresse 
et al. 2012). Approximately 4–24% of IgA-producing intestinal plasma cells are specific for 
TG2 and 1% for DGP (Di Niro et al. 2016; Iversen et al. 2015; Steinsbo et al. 2014). 
Anti-TG2 autoantibodies have been found to be a more specific hallmark of CD compared to 
anti-DGP antibodies (Iversen et al. 2015). Both anti-DGP antibodies and anti-TG2 
autoantibodies are present in the circulation, and anti-TG2 autoantibodies are also found as 
deposits in the basement membrane of the small-intestinal mucosa along the villous and crypt 
epithelium and around blood vessels (Korponay-Szabo et al. 2004; Mesin et al. 2012; 
Stamnaes and Sollid 2015). These deposits are highly specific for CD, and they seem to 
precede and predict the histological changes (Salmi et al. 2006; Tosco et al. 2008). Anti-TG2 
autoantibodies have also extra-intestinal target sites in other organs, such as liver, muscles, 
and kidney (Korponay-Szabo et al. 2004). 
11 
 
IgA is locally secreted in the LP of the small intestine, where it binds to polymeric Ig receptor 
and is actively transported into the luminal region (Spencer and Sollid 2016). IgA is mostly 
dimeric in the intestinal area and consists of IgA1 and IgA2 subclasses, whereas in serum IgA 
is mostly in monomeric form (Spencer and Sollid 2016).  
In normal small-intestinal mucosa, IgA antibodies can be detected inside the plasma and 
epithelial cells, but they do not target TG2 (Hietikko et al. 2018). In CD, there exists TG2-
specific plasma cells in the small-intestinal mucosa that secrete IgA autoantibodies against 
TG2, and data by Di Niro and co-workers indicates that TG2-specific autoantibodies located 
in serum are secreted by plasma cells that are clonally related to intestinal TG2-specific 
plasma cells but reside outside the small intestine (Di Niro et al. 2016). 
Several other autoantibodies have been found in CD-patients, such as autoantibodies against 
actin (Clemente et al. 2000), calreticulin (Tuckova et al. 1997), desmin (Teesalu et al. 2001), 
and transglutaminase 3 (Salmi et al. 2016). The role of these autoantibodies in the 
pathogenesis and diagnosis of CD is still unknown. However, autoantibodies targeting 
transglutaminase 3 have been associated with dermatitis herpetiformis (Salmi et al. 2016). 
2.3.2 Role of antibodies in coeliac disease 
The exact role of anti-TG2 and anti-DGP antibodies in the pathogenesis of CD is still unclear 
(Stamnaes and Sollid 2015). Secretory CD-specific IgA is suggested to mediate the 
transcytosis of gluten-derived peptides through the intestinal epithelium by binding to a 
transferrin receptor CD71, which is overexpressed in CD-patients (Lebreton et al. 2012; 
Matysiak-Budnik et al. 2008; Rauhavirta et al. 2011). It has been shown that TG2-targeting 
IgD, and to a minor extent IgM, expressed on B cell surface can become cross-linked by TG2 
and form a multimerized receptor that may promote the activation of TG2-specific B cells (Di 
Niro et al. 2012; Giersiepen et al. 2012; Iversen et al. 2015). It has also been suggested that 
TG2-specific autoantibodies may affect the function and activity of TG2, but thus far, the 
results have been contradictory (Byrne et al. 2010; Myrsky et al. 2009). On the other hand, the 
role of TG2-specific B cells as potential APCs for gluten-reactive T cells may suggest that the 
B cells participate in the pathogenesis of CD by amplifying the anti-gluten T cell response 
rather than the antibodies themselves (Stamnaes and Sollid 2015). 
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2.4 Development of B cells in coeliac disease 
The generation of TG2-targeting B cells and plasma cells in GALT has a major role in CD, as 
TG2 is considered the main autoantigen of CD (Mesin et al. 2012). However, a high number 
of studies on the development of B cells in the GALT are based on mice, and therefore most 
of the current knowledge may not be applicable when comparing to human B cell 
development (Knoop and Newberry 2012). 
In mice, PPs have been considered as the primary induction site of mucosal IgA-producing B 
cells (Knoop and Newberry 2012). However, recent studies have demonstrated that murine 
ILFs can also induce B cell maturation and IgA response (Knoop and Newberry 2012). Next, 
I will discuss the basic development of human B cells, the development and role of ILFs, and 
the development of TG2-specific B cells in CD. 
2.4.1 Development of B cells 
The development of B cells is based on the formation of antigen-recognizing BCRs. These 
receptors contain an Ig superfamily structure, which forms the recognition site against an 
antigen (Rothenberg 2014). The Ig structure is made of two identical Ig heavy chains and two 
identical Ig light chains that are assembled into disulfide-bonded heterodimers (Rothenberg 
2014). A single gene encodes the Ig heavy chain, whereas two different genes, Igκ and Igλ, 
encode the Ig light chain (Rothenberg 2014). Each of the three gene loci contains a variable 
and a constant region. The variable region consists of variable (V), diversity (D), and joining 
(J) segments. Ig heavy chain contains VH, DH, and LH segments, whereas Ig light chain 
contains VL and JL segments. 
The development of B cells initiates in the bone marrow, which contains pluripotent 
hematopoietic stem cells (HSCs). These cells differentiate first into multipotent progenitors, 
which then give rise to common lymphoid progenitors (CLPs). The activation of B cell 
developmental pathway is induced by transcription factors E box binding protein 2A (E2A) 
and early B cell factor 1 (EBF1; Ramirez et al. 2010; Rothenberg 2014). After the initiation of 
differentiation, E2A and EBF1 activate transcription factors Ikaros and Pax5 in pro-B cells 
that induce the beginning of genetic recombination and expression of proteins required for the 
display of pre- and mature BCRs (Ramirez et al. 2010; Rothenberg 2014). In addition, pro-B 
cells activate the expression of CD19 (Rothenberg 2014). Pax5 is considered as the 
commitment factor that maintains the B cell identity by activating B cell-specific genes and 
repressing genes associated with other cell lineages (Medvedovic et al. 2011).  
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Genes encoding BCR are assembled in a somatic gene rearrangement, known as the V(D)J 
recombination, in which VDJ-segments are joined through successive rearrangements (He et 
al. 2007). The V(D)J recombination is mediated by proteins RAG1 and RAG2 (Rothenberg 
2014). According to the current knowledge, the expression of both RAG1 and RAG2 is 
limited to B cell and T cell lineages (Rothenberg 2014). The rearrangement initiates on genes 
that encode the Ig heavy chain (Rothenberg 2014). The progression of the development 
depends the success of the rearrangement, which is verified in the primary development 
checkpoint during the transition from pro-B cell stage to pre-B cell stage (Rothenberg 2014). 
After successful verification, the pre-B cells rearrange the gene segments coding for the Igκ 
or Igλ light chain genes (Rothenberg 2014). The V(D)J rearrangement produces surface IgM 
positive mature naïve B cells with a large antibody repertoire (Chen et al. 2009). After the 
BCRs are maturated, mature naïve B cells migrate from the bone marrow to colonize 
secondary lymphoid organs, including the GALT (Ramirez et al. 2010). In the GALT, B cells 
acquire surface IgD of the same specificity as IgM by going through alternative splicing of 
the Ig heavy chain constant region (Chen et al. 2009). 
Mature naïve B cells localize to the different lymphoid tissue structures that contain lymphoid 
follicles. After encountering an antigen, mature naïve B cells encounter CD4
+
 T cells at the 
border of the lymphoid follicle and the interfollicular CD4
+
 T cell zone for cognate interaction 
and undergo a secondary diversification, known as somatic hypermutation (SHM), in which 
amino acid sequence in the variable regions of the Ig is altered to enhance the binding affinity 
and specificity of the BCR and antibodies (Zan and Casali 2013). SHM forms an expansion of 
affinity-matured mutant B cell clones with high-affinity antibodies.  
Constant segments that are proximal to the variable region can be deleted through a 
mechanism known as class-switch recombination (CSR), which generates IgA, IgG, and IgE 
subtypes with the same antigen binding specificity as IgM (Chen et al. 2009; Zan and Casali 
2013). CSR occurs through either a T cell-dependent follicular pathway or T cell-independent 
extra-follicular pathway. T cell-dependent pathway is mediated by antigen-activated CD4
+
 T 
cells located in the CD4
+
 T cell zone. These cells express tumor necrosis factor (TNF) 
superfamily member CD40L, which promotes CSR by binding to the CD40 receptor on B 
cells (Chen et al. 2009; Knoop and Newberry 2012). This also increases the expression of 
enzyme activation-induced cytidine deaminase (AID), which promotes both CSR and SHM of 
the Ig genes (Knoop and Newberry 2012; Mesin et al. 2012). T cell-independent pathway is 
mediated by antigen-activated DCs, macrophages, and intestinal epithelial cells. These cells 
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secrete TNF superfamily members B cell activating factor and a proliferation-inducing ligand, 
which bind to their corresponding receptors on B cells (Chen et al. 2009; Spencer and Sollid 
2016). B cells that undergo T cell-dependent pathway are associated with extensive SHM, 
whereas B cells expanding in T cell-independent pathway acquire fewer mutations (Mesin et 
al. 2012). 
B cells undergo SHM and CSR in germinal centers that are associated with the T cell-
dependent pathway (Mesin et al. 2012). Germinal centers are located in the lymphoid follicles 
of PPs and ILFs (Mesin et al. 2012). B cells in germinal centers are surrounded by other cells 
that support the clonal expansion and selection of the B cells, including follicle DCs, 
follicular T cells, and macrophages (Spencer and Sollid 2016). Germinal centers are 
surrounded by a mantle zone consisting of CD27
-
IgM
+
IgD
+
 mature naïve B cells (Spencer and 
Sollid 2016). The mantle zone is surrounded by a marginal zone consisting of B cells which 
do not express IgD (Spencer and Sollid 2016). Each germinal center appears to represent a 
clone of cells derived from one antigen-stimulated lymphocyte (Mesin et al. 2012). 
GALT germinal center initiation requires CD40-mediated signal from T cells, although 
germinal center -associated B cell and IgA responses may not always require cognate T cell 
and B cell interactions (Mesin et al. 2012). In fact, it has been observed that germinal centers 
can form in PPs based on BCR specificity without requiring interaction between T cells and B 
cells (Mesin et al. 2012). Furthermore, it has been suggested that germinal centers are not 
essential for antibody formation and may be involved in long-term antibody responses 
(Spencer and Sollid 2016). 
After CSR, mature naïve B cells differentiate into plasmablasts (Spencer and Sollid 2016). 
During the differentiation, the expression of EBF1 and Pax5 is silenced (Rothenberg 2014). 
Plasmablasts produce less antibodies than plasma cells and are characterized by the 
expression of proliferation marker Ki-67, which is devoid in the plasma cells (Mesin et al. 
2012). Plasmablasts can enter the blood through the lymphatic system and home back to the 
intestine, where they finally maturate into plasma cells and are guided to the intestinal LP by 
chemokines from intestinal epithelial cells (He et al. 2007; Spencer and Sollid 2016). The 
main phases of the human intestinal B cell development are illustrated in Figure 5. 
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Figure 5. Developmental pathway of human intestinal B cells. The main phases of the B 
cell development, the expression of stage-specific factors, and the location of the development 
stages are illustrated in this figure. Hematopoietic stem cells (HSCs) in the bone marrow first 
differentiate into common lymphoid progenitors (CLPs), which give rise to B cell lineage due 
to expression of early B cell factor 1 (EBF1), E box binding protein 2A (E2A), Pax5, and 
Ikaros. CD19
+
 progenitor B cells undergo VDJ-recombination mediated by RAG1 and RAG2, 
in which Ig heavy and Ig light chains are rearranged and the B cell receptor (BCR) is 
assembled as IgM and IgD. Mature naïve B cells migrate to GALT and undergo somatic 
hypermutation (SHM) and class-switch recombination (CSR) that are initiated by activation-
induced cytidine deaminase (AID). B cells differentiate into IgA
+
 or IgG
+
 plasmablasts which 
migrate to blood. After homing back to GALT, plasmablasts mature into plasma cells that 
produce antibodies of the same Ig class and specificity of the BCR. Figure drawn according to 
Ramirez et al. 2010, Rothenberg 2014, and Spencer and Sollid 2016. 
Plasma cells are non-proliferating cells that serve as antibody-secreting cells in the bone 
marrow or mucosal tissue, including the small intestine (Spencer and Sollid 2016). LP of the 
small intestine contains terminally differentiated plasma cells, which are maintained by the 
local supportive microenvironment (Mesin et al. 2012). Plasma cells are localized throughout 
the LP, although most of the cells occupy the diffuse subepithelial connective tissue (Spencer 
and Sollid 2016). The intestinal LP also contains macrophages, DCs, and neutrophils, which 
may participate in the plasma cell production (Mesin et al. 2012). In mice, DCs produce TNF 
superfamily members that promote IgA production in B cells expressing complementary 
receptors (Knoop and Newberry 2012). 
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Plasma cells are characterized by the cell markers CD138 and CD27, whereas the expression 
of CD19 and CD45 is more heterogeneous (Mesin et al. 2012). Intestinal plasma cell 
repertoire consists of both unmutated IgA antibodies and somatically mutated IgA antibodies 
(Mesin et al. 2012). Mature plasma cells cannot switch antibody classes (Spencer and Sollid 
2016). According to Spencer and Sollid, plasma cells in the small intestine and serum express 
lower levels of surface IgA than corresponding memory B cells (Spencer and Sollid 2016). 
2.4.2 Development and function of isolated lymphoid follicles 
The function and development of ILFs in humans is not well understood. However, there have 
been many studies on murine ILFs. Therefore, most of the current knowledge about ILFs is 
based on mice, which may differ significantly from human ILFs. 
ILFs are compact structures filled with closely packed lymphocytes that appear postnatally 
throughout the small intestine, ranging from early phase cryptopatches to fully matured ILFs 
(Buettner and Lochner 2016). In mice, ILFs are located at the base of a crypt or in villi that 
are thicker and shorter in a longitudinal section than the surrounding normal villi (Hamada et 
al. 2002; Lorenz and Newberry 2004). Similarly to PPs, ILFs contain a large B cell area with 
a germinal center, covered with FAE and CD4
+
 T cells (Mesin et al. 2012). However, unlike 
PPs, ILFs lack distinct interfollicular T cell zones (Wang et al. 2006). Murine ILFs contain 
mostly immature CD19
+
 B cells that have not yet gone through CSR (Knoop and Newberry 
2012). In mice, most of the B cells display B220
+
CD19
+
CD23
+
IgM
low
IgD
high
CD5
-
Mac-1
- 
phenotype that express stem cell factor c-kit, and a smaller subset express IgA
+
 (Hamada et al. 
2002; Pabst et al. 2005).  
Because the structure of ILFs shares similarities with PPs, ILFs are also assumed as inductive 
sites for intestinal immune reactions (Pabst et al. 2005). According to Tsuji and co-workers, 
ILFs contribute significantly to IgA synthesis in the small intestine of mice (Tsuji et al. 2008). 
Unlike to T cell-dependent IgA response in the lymphoid follicles of PPs, the activation of B 
cells and induction of AID for IgA CSR in the murine ILFs may not require T cell 
interactions (Tsuji et al. 2008). Instead, the activation of B cells appears to be mediated only 
by ILF DCs, and many AID-expressing B cells are located close to these DCs (Tsuji et al. 
2008). 
Cryptopatches are aggregates of lymphoid tissue inducer (LTi) cells and lymphoid tissue 
organizer (LTo) cells that act as precursors to ILFs (Knoop and Newberry 2012; Nochi et al. 
2013). In mice, intestinal epithelial cells produce IL-7 that binds to the IL-7 receptor on LTi 
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cells. This induces the expression of lymphotoxin α1β2 that binds to the lymphotoxin β 
receptor on LTo cells and up-regulates the expression of various chemokines and adhesion 
molecules that participate in the recruitment and retention of lymphocytes into cryptopatches 
(Hamada et al. 2002; Nochi et al. 2013). Cryptopatches can develop into ILFs in response to 
signal from the commensal microbiota (Knoop and Newberry 2012). In mice, the amount of 
cryptopatches can outnumber ILFs (Knoop and Newberry 2012). The genesis and function of 
cryptopatches in human GALT is not well understood (Nochi et al. 2013). However, in a 
study performed by Nochi and co-workers, they found out that murine cryptopatches can 
initiate human GALT genesis (Nochi et al. 2013).  
According to the current knowledge, de novo development of murine cryptopatches does not 
occur throughout adulthood (Knoop and Newberry 2012). Instead, cryptopatches may develop 
into ILFs throughout adulthood as an immune response (Knoop and Newberry 2012). In fact, 
the development and function of ILFs is considered to be more dynamic than of PPs because 
the amount, size, and cellular composition of ILFs can highly vary, depending on the antigen 
load in the intestine (Knoop and Newberry 2012; Tsuji et al. 2008). Pabst and co-workers 
found out that in mice, the size, location, and cellular composition of lymphoid aggregations 
are heterogeneous and that most lymphoid structures cannot be classified neither as ILF or 
cryptopatch (Pabst et al. 2005). According to their study, the size and formation of aggregated 
lymphoid structures depends on the strain and age of studied animals (Pabst et al. 2005). 
Therefore, comparing data obtained from different species at different ages can be difficult, as 
the developmental speed varies between species (Pabst et al. 2005). 
2.4.3 Current concept of the development of transglutaminase 2-specific B cells 
TG2-specific plasma cells represent 5–25% of all plasma cells in the coeliac lesion with a 
limited number of clones, which suggests a huge clonal expansion in the small intestine 
(Stamnaes and Sollid 2015). The reason why intestinal TG2-specific plasma cells have fewer 
mutations than other plasma cells in the intestinal LP is not known. The low mutation rate 
could be related to T cells that provide help to TG2-specific B cells via TG2-DGP complexes 
(Spencer and Sollid 2016). According to Mesin and co-workers, intestinal anti-TG2 
autoantibody repertoire has a very limited number of somatic mutations in the Ig heavy chain 
encoded by VH5 gene, which could be related to the structural properties of the VH5 region 
(Mesin et al. 2012). In addition, all VH5 antibodies do not bind to TG2, which shows that the 
anti-TG2 reactivity does not depend on unspecific binding of the VH5 region (Di Niro et al. 
2012). 
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Besides the uniquely limited number of mutations, it is not well understood where the 
development of TG2-specific B cells takes place, and whether it is T cell-dependent or T cell-
independent (Mesin et al. 2012). It is assumed that in mice, the IgA responses generated in 
lymphoid follicles require the T cell-dependent pathway, whereas extra-follicular IgA 
responses are T cell-independent (Tsuji et al. 2008). T cell-dependent pathway in germinal 
centers commonly results in long-lived plasma cells that sustain antigen-specific response for 
decades (Iversen et al. 2015). However, intestinal TG2-specific plasma cells have been 
observed to disappear within a month after patients commence GFD, which indicates that 
intestinal TG2-specific plasma cells are not long-lived (Di Niro et al. 2016). Furthermore, 
SHM and AID-mediated CSR have been observed to occur outside of germinal centers in 
both mice and humans, suggesting that intestinal immature B cells can develop directly in the 
LP (Di Niro et al. 2016; He et al. 2007; Mesin et al. 2012). Therefore, it has been suggested 
that TG2-specific B cells may develop at extra-follicular sites without germinal center 
reactions (Iversen et al. 2015; Mesin et al. 2012). This theory is further supported by the 
scarce SHM, which suggests that the development either occurs via T cell-independent 
pathway without germinal center formation, or the cells undergo limited rounds of selection in 
a germinal center (Mesin et al. 2012). In a study performed by Di Niro and co-workers, they 
could not detect AID in TG2 positive plasmablasts in the small intestine, which suggests that 
TG2-specific B cells may undergo CSR outside the small-intestinal mucosa (Di Niro et al. 
2012). 
Even if the TG2-specific B cells would develop at extra-follicular sites, T cells could still be 
involved in the response, as the clinical observation of anti-TG2 autoantibodies is strictly 
gluten- and HLA-dependent (Di Niro et al. 2012). This is further supported by Di Niro and 
co-workers who observed that B cells engineered to express an anti-TG2 BCR could process 
and present TG2-DGP complexes, resulting in activation of gluten-specific CD4
+
 T cells 
which in turn activate the B cells (Di Niro et al. 2012). 
Most of the studies on the development of human TG2-specific B cells have been based on 
isolated TG2-specific plasma cells derived from CD-patients’ small intestine, which is 
insufficient for studying the earlier phases of B cell development as majority of the 
development occurs in GALT (Spencer and Sollid 2016). Access to GALT structures of CD-
patients would help to dissect this, but so far this has been restricted due to ethical aspects and 
methodological limitations (Spencer and Sollid 2016).  
19 
 
3 Objectives 
The aim of this thesis was to investigate the presence of early phase TG2-specific B cells in 
the duodenal bulb and to determine whether they are located in the lymphoid follicles or at 
extra-follicular sites. The first phase was to screen cryosected duodenal bulb biopsy 
specimens from untreated CD-patients and non-CD controls to identify specimens containing 
ILFs or other lymphoid tissues. The second phase was to detect early phase TG2-specific B 
cells using both direct and indirect immunofluorescence staining and co-localization with 
TG2 and antibodies against immature B cell markers. 
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4 Materials and Methods 
4.1 Screening of duodenal bulb biopsies 
The first phase of the study was to screen 211 duodenal bulb biopsy specimens from Finnish 
children and 268 specimens from Romanian children and adults to identify specimens with 
potential ILFs, PPs, or diffuse lymphoid tissue. The specimens had been collected from both 
untreated CD-patients and healthy individuals. Finnish and Romanian specimens were used 
due to accessibility. The specimens consisted of cryosected, 5-μm-thick sections stained using 
immunohistochemistry to evaluate CD latency. Each specimen consisted of three slides, and 
each slide contained three identically stained sections. The sections had been stained using 
monoclonal antibodies against TCRαβ+, TCRγδ+, or HLA-DR. The screening was performed 
blinded to prevent possible bias. Specimens were observed using Olympus BX60 microscope 
(Olympus, Tokyo, Japan) and images were acquired using Olympus Colorview camera and 
edited with CellD image software (Olympus Soft Imaging Solutions GmbH, Muenster, 
Germany). 
A total of 16 specimens with most potential lymphoid tissue structures were selected for the 
immunofluorescence staining optimization. New 5-μm-thick sections were cut from the 
original biopsy specimens, and three sections were layered on each slide. The slides were 
stored at –20°C until they were stained.  
4.2 Immunofluorescence staining of duodenal bulb biopsies 
Both direct and indirect immunofluorescence staining methods were based mainly on 
protocols by Di Niro and co-workers, and Hietikko and co-workers (Di Niro et al. 2012; 
Hietikko et al. 2018). First, the protocol was optimized for the blocking, washing, and 
incubation phases of the recombinant TG2 (rTG2) and direct IgA immunofluorescence 
stainings by using the selected duodenal bulb biopsies and additional small intestine biopsies. 
The entire protocol was performed at room temperature. In the optimized protocol, the slides 
were first air-dried for 20 min and then fixed in 96% alcohol – acetone for 3 min, as it is 
commonly used for cryosected tissue sections (Dominguez-Sola and Cattoretti 2017). After 
the fixation, the slides were air-dried for 2 min and washed with phosphate-buffered saline 
(PBS) for 3 × 2 min. The slides were blocked to prevent unspecific binding by using 5% milk 
powder – 5% bovine serum albumin (BSA) – 5% normal goat serum 30 µl/section for 30 min 
in a moisturized chamber. For rTG2 staining, the sections were incubated with biotinylated 
human rTG2 (1:100; T002, Zedira, Darmstadt, Germany) 30 µl/section for 60 min in a 
21 
 
moisturized chamber. To detect the rTG2, the sections were incubated with 
tetramethylrhodamine isothiocyanate (TRITC)-conjugated streptavidin (1:100; 43-4314, 
Invitrogen, Paisley, UK) 30 µl/section for 30 min in a moisturized chamber while protected 
from light. For direct IgA stainings, the sections were incubated with fluorescein 
isothiocyanate (FITC)-conjugated rabbit anti-human anti-IgA antibody (1:40; F0204, Dako 
A/S, Glostrup, Denmark) or TRITC-conjugated goat anti-human anti-IgA antibody (1:40; 
A18786, Thermo Fisher Scientific, Waltham, USA) 30 µl/section for 60 min in a moisturized 
chamber. TRITC-conjugated streptavidin was used as a secondary control for rTG2 and IgA-
TRITC. For IgA-FITC, no secondary control was available. All dilutions were made in 5% 
milk powder – 5% BSA. The slides were washed with 0.05% TWEEN – PBS for 3 × 5 min 
between and after the incubations. Finally, the slides were mounted with 4',6-diamidino-2-
phenylindole (DAPI)-containing VectaShield Mounting Medium (H-1200, Vector 
Laboratories, Burlingame, USA) and a cover glass. DAPI was used to counterstain nuclei. 
Stained slides were stored at +4°C for shorter periods and at –20°C for longer periods while 
protected from light. 
Indirect immunofluorescence staining was based on the optimized protocol. After the 
blocking phase, the sections were incubated with primary antibody dilutions 30 µl/section for 
60 min in a moisturized chamber. In secondary controls, 30 µl 5% milk powder – 5% BSA 
was used for each section in the primary incubation. After the primary incubation, the sections 
were incubated with appropriate secondary antibody dilutions 30 µl/section for 30 min in a 
moisturized chamber while protected from light. All used antibodies were diluted in 5% milk 
powder – 5% BSA. A description of the primary and secondary antibodies used in this study 
is provided in Table 1 and Table 2. The slides were washed with 0.05% TWEEN – PBS for 3 
× 5 min between and after the incubations. The rest of the protocol was the same as in the 
optimized rTG2 and IgA immunofluorescence stainings. 
Table 1. Primary anti-human antibody dilutions used in the indirect 
immunofluorescence staining. 
Antibody Host species Dilution  Catalogue Manufacturer 
Anti-IgD Rabbit 1:25 ab195581 Abcam, Cambridge, UK 
Anti-IgM  Mouse 1:25 9020-01 Southern Biotech, Birmingham, USA 
Anti-AID Rat 1:100 #4959 Cell Signaling Technology, Danvers, USA 
Anti-Pax5 Mouse 1:250 SC-13146 Santa Cruz Biotechnology, Dallas, USA 
AID: activation-induced cytidine deaminase 
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Table 2. Secondary antibody dilutions used in the indirect immunofluorescence staining. 
Antibody Host 
species 
Dilution  Catalogue Manufacturer 
Alexa Fluor 488 anti-rabbit Goat 1:500 A11034 Life Technologies, Carlsbad, USA 
Alexa Fluor 568 anti-rabbit Goat 1:500 A11036 Life Technologies 
Alexa Fluor 488 anti-mouse Goat 1:500 A11001 Invitrogen 
Alexa Fluor 488 anti-rat Donkey 1:500 A21208 Invitrogen 
Alexa Fluor 568 anti-rat Donkey 1:500 ab175475 Abcam 
 
After the optimization phase, four specimens from untreated CD-patients and three specimens 
from non-CD controls were selected for the final immunofluorescence staining. Fixation was 
not included in the final staining because it may affect the three-dimensional structure of the 
epitopes in the specimens, and therefore decrease the quality of the staining. The final staining 
material consisted of rTG2 to detect TG2-specific B cells and plasma cells, antibodies against 
IgA to detect IgA-specific B cells and plasma cells, antibodies against IgD and IgM to detect 
early phase B cells, and antibodies against AID and Pax5 to detect developing B cells. All 
used staining combinations for the co-localizations are described in Table 3. 
Table 3. Immunofluorescence double staining combinations and the target of the co-
localization. The emission wavelength (488 nm = green, 568 nm = red) of TRITC, FITC, and 
the secondary antibodies is described for each primary antibody. 
Combination Target 
rTG2 (568) + IgA-FITC (488) Mature naïve TG2-specific B cells, plasmablasts, or plasma cells 
rTG2 (568) + IgD (488) Early phase TG2-specific B cells before class-switch 
rTG2 (568) + IgM (488) Early phase TG2-specific B cells before class-switch 
rTG2 (568) + AID (488) TG2-specific B cells with ongoing IgA class-switch 
rTG2 (568) + Pax5 (488) TG2-specific B cells before transition into plasma cells 
IgA-TRITC (568) + AID (488) B cells with ongoing IgA class-switch 
IgA-TRITC (568) + Pax5 (488) IgA-specific B cells before transition into plasma cells 
IgD (488) + AID (568) B cells with ongoing class-switch 
IgD (568) + Pax5 (488) Early phase B cells 
AID: activation-induced cytidine deaminase; FITC: fluorescein isothiocyanate; rTG2: 
recombinant transglutaminase 2; TRITC: tetramethylrhodamine isothiocyanate 
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4.3 Fluorescence microscopy of duodenal bulb biopsies 
During the immunofluorescence staining optimization phase, the specimens were observed 
with widefield fluorescence using Olympus BX60 microscope or Olympus IX51 Fluorescence 
Microscope. Images were acquired using Olympus BX60 microscope with Olympus 
Colorview camera and CellD image software, or Olympus IX51 microscope with Olympus 
DP30BW camera and DP manager software (Olympus). For the final staining, only Olympus 
IX51 microscope was used. The same exposure time was used for all specimens of each 
staining combination. All images were organized using ImageJ software (Rasband WS, 
ImageJ, National Institute of Mental Health, Bethesda, USA; Schneider et al. 2012). 
4.4 Ethical considerations 
The material of this study consisted of duodenal bulb and small intestine biopsy cryosections 
from prospectively collected cohorts. The specimens were collected from healthy and CD-
affected Finnish and Romanian individuals. The collection and use of Finnish specimens was 
approved by Ethics Committee of the Pirkanmaa Hospital District (ethical approval R11187), 
and the collection and use of Romanian specimens was approved by University of Medicine 
and Pharmacy Carol Davila and National Institute for Mother and Child Health (ethical 
approvals 20534.2011 and 8971.2017). The specimens were kindly provided by acting 
professor and pediatric gastroenterologist Kalle Kurppa, and pediatric gastroenterologist Alina 
Popp.  
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5 Results 
5.1 Identification of lymphoid structures in duodenal bulb biopsies 
The study comprised 479 screened cryosected duodenal bulb biopsy specimens. Out of all the 
screened specimens, 67 (14.0%) contained structures resembling ILFs, 13 (2.70%) contained 
structures resembling PPs, 62 (12.9%) contained structures resembling diffuse lymphoid 
tissue, and the reminder 337 (70.4%) did not contain any recognizable lymphoid structures. 
The specimens that contained lymphoid tissue structures were evaluated, and the 16 most 
high-quality specimens were selected for the immunofluorescence staining optimization. For 
the final staining, seven pediatric specimens were selected, which included three specimens 
from Finnish untreated CD-patients, two specimens from non-CD Finnish individuals, one 
specimen from a Romanian untreated CD-patient, and one specimen from a non-CD 
Romanian individual. More detailed information is provided in Table 4 and Table 5. Every 
specimen included a structure resembling ILF, PP, or diffuse lymphoid tissue, which are 
shown in Figure 6 and Figure 7. 
Table 4. Selected untreated coeliac disease patient duodenal bulb biopsy specimens for 
the immunofluorescence staining. Nationality and the found lymphoid tissue structures are 
described for each coeliac disease (CD)-patient. In addition, the diagnostic information has 
been provided, including endomysial antibody (EmA) dilutions and anti-transglutaminase 2 
(TG2) autoantibody values from serum samples, and the number of CD-associated cells and 
IgA deposits in duodenal bulb biopsies. EmA dilution 1:≥5 is considered positive. The cut-off 
value for TG2 is >5 AU/ml. The reference values are 37 cells/mm for CD3
+
 intraepithelial 
lymphocytes (IELs) and 4.3 cells/mm for T cell receptor (TCR)-γδ+ IELs. IgA deposits were 
graded from 0 (negative) to 3 (high). All reference values were from Hietikko and co-workers 
(Hietikko et al. 2018). 
Untreated 
CD-patient 
Nationality EmA 
dilution 
TG2 
(AU/ml) 
Cells/mm IgA deposits Found structures 
1 Finnish 1:100 22 N/A N/A Isolated lymphoid 
follicle or Peyer’s 
patch 
2 Finnish 1:500 112 CD3+ 65  
TCRγδ+ 18 
>3 Isolated lymphoid 
follicle or diffuse 
lymphoid tissue 
3 Finnish 1:50 15 CD3+ 106 
TCRγδ+ 42 
>3 Diffuse lymphoid 
tissue 
4 Romanian N/A N/A N/A N/A Isolated lymphoid 
follicle or diffuse 
lymphoid tissue 
N/A: data not available 
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Figure 6. Brightfield images of the selected untreated coeliac disease patient duodenal 
bulb biopsy specimens. The specimens had been stained using immunohistochemistry to 
detect T cell receptor (TCR)-αβ+ or TCRγδ+ T cells. Structures that resemble lymphoid tissue 
are marked with a circle. Images were acquired using Olympus BX60 microscope with 
magnification ×10. Scale bar = 200 μm. CD: coeliac disease 
Table 5. Selected non-coeliac control duodenal bulb biopsy specimens for the 
immunofluorescence staining. Nationality and the found lymphoid tissue structures are 
described for each control. In addition, the diagnostic information has been provided, 
including endomysial antibody (EmA) dilutions and anti-transglutaminase 2 (TG2) 
autoantibody values from serum samples, and the number of CD-associated cells and IgA 
deposits in duodenal bulb biopsies. EmA dilution 1:≥5 is considered positive. The cut-off 
value for TG2 is >5 AU/ml. The reference values are 37 cells/mm for CD3
+
 intraepithelial 
lymphocytes (IELs) and 4.3 cells/mm for T cell receptor (TCR)-γδ+ IELs. IgA deposits were 
graded from 0 (negative) to 3 (high). All reference values were from Hietikko and co-workers 
(Hietikko et al. 2018). 
Control Nationality EmA 
dilution 
TG2 
(AU/ml) 
Cells/mm IgA deposits Found structures 
1 Finnish 1:5 Negative CD3+ 16 
TCRγδ+ 5.1 
Negative Isolated lymphoid 
follicle 
2 Finnish Negative Negative CD3+ 20  
TCRγδ+ 2 
Negative Isolated lymphoid 
follicle or Peyer’s 
patch 
3 Romanian N/A N/A N/A N/A Diffuse lymphoid 
tissue 
N/A: data not available 
 
Figure 7. Brightfield images of the selected non-coeliac control duodenal bulb biopsy 
specimens. The specimens had been stained using immunohistochemistry to detect T cell 
receptor (TCR)-γδ+ T cells. Structures that resemble lymphoid tissue are marked with a circle. 
Images were acquired using Olympus BX60 microscope with magnification ×10. Scale bar = 
200 μm. 
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5.2 Optimization of immunofluorescence staining 
In the optimization of the immunofluorescence staining protocol, the primary aim was to find 
optimal concentrations for the staining incubations. The initial concentrations for antibodies 
against IgD and IgM were 1:100, 1:250, and 1:500, which are represented in Figure 8. The 
dilutions were chosen based on an article by Chen and co-workers (Chen et al. 2009). 
Because the dilutions did not appear to reduce the background staining, a higher concentration 
of 1:25 was decided to use for both antibodies, which is shown in Figure 9. By adding 0.05% 
TWEEN to the PBS washing buffer that was used between and after incubations, unspecific 
binding decreased as seen when comparing Figure 8 and Figure 9. The specimens in Figure 9 
were washed with 0.05% TWEEN – PBS, whereas the specimens in Figure 8 were washed 
with PBS only. 
 
Figure 8. Concentration optimization for the antibodies against IgD and IgM using 
dilutions 1:100, 1:250, and 1:500. Images of IgD and IgM were taken from the same 
duodenal bulb biopsy specimen. All specimens were washed with phosphate-buffered saline 
only. IgD and IgM are shown in green and DAPI in blue. Positive cells are marked with an 
arrow. Fluorescence images were acquired using Olympus BX60 microscope with 
magnification ×20. Scale bar = 100 μm. 2nd Ctrl: secondary control 
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Figure 9. Concentration optimization for the antibodies against IgD and IgM using 
dilution 1:25. All duodenal bulb biopsy specimens were washed with 0.05% TWEEN – 
phosphate-buffered saline. IgD and IgM are shown in green and DAPI in blue. Positive cells 
are marked with an arrow. Fluorescence images were acquired using Olympus BX60 
microscope with magnification ×20. Scale bar = 100 μm. 2nd Ctrl: secondary control 
 
The concentrations were also optimized for rTG2 and antibodies against AID and Pax5. For 
rTG2, a dilution of 1:100 was used, which is shown in Figure 10. The dilution was chosen 
based on an article by Hietikko and co-workers (Hietikko et al. 2018). In addition, a positive 
control test was performed with rTG2 using small intestine biopsy sections from CD-affected 
individuals. The initiate dilutions for AID and Pax5 were 1:50, 1:100, and 1:250, which are 
represented in Figure 11. Dilutions that achieved optimal results were 1:100 for AID and 
1:250 for Pax5. For the final staining, IgA-FITC and IgA-TRITC were used at a dilution of 
1:40, which was based on the protocol by Hietikko and co-workers (Hietikko et al. 2018). 
Because fixation may alter the structure of the desired epitopes, a specimen was tested 
without using fixation. According to the results, there was no significant difference in the 
quality of the staining. Therefore, fixation was decided to not be included in the final staining. 
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Figure 10. Concentration optimization for recombinant transglutaminase 2 using 
dilution 1:100 and a duodenal bulb biopsy specimen from an untreated CD-patient. 
Recombinant transglutaminase (rTG2) is shown in red and DAPI in blue. Positive cells are 
marked with an arrow. Fluorescence images were acquired using Olympus BX60 microscope 
with magnification ×20. Scale bar = 100 μm. 2nd Ctrl: secondary control 
 
Figure 11. Concentration optimization for the antibodies against activation-induced 
cytidine deaminase (AID) and Pax5 using dilutions 1:50, 1:100, and 1:250. Images of AID 
and Pax5 were taken from the same duodenal bulb biopsy specimen. AID is shown in red, 
Pax5 in green, and DAPI in blue. Positive cells are marked with an arrow. Fluorescence 
images were acquired using Olympus BX60 microscope with magnification ×20. Scale bar = 
100 μm. 2nd Ctrl: secondary control 
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5.3 Identification of B cells in duodenal bulb biopsies 
The selected four untreated CD-patient and three non-CD control duodenal bulb biopsy 
specimens were stained using different rTG2 and antibody combinations to identify B cells 
and lymphoid structures. Combination rTG2-IgA was used to identify mature naïve TG2-
specific B cells that had gone through CSR, TG2-specific plasmablasts, or TG2-specific 
plasma cells. Combinations rTG2-IgD and rTG2-IgM were used to detect early phase TG2-
specific B cells that had yet to undergo CSR. Combination rTG2-AID was used to detect 
TG2-specific B cells with ongoing CSR. Combination rTG2-Pax5 was used to detect TG2-
specific B cells that had not yet matured into plasma cells. In addition, IgA and IgD combined 
with AID and Pax5 were used to detect all early phase B cells regardless of their antigen 
specificity. Next, I will present the results of each staining combination. 
First, the presence of IgA positive and TG2-specific B cells, plasmablasts, and plasma cells 
was investigated using rTG2-IgA combination. A single co-localization was detected in three 
untreated CD-patient sections, whereas no co-localizations were detected in non-CD controls. 
All three double positive cells were located in the neck of a villus. The number of IgA single 
positive cells was high in all sections. Results are presented in Figure 12. 
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Figure 12. Representative images of immunofluorescence double staining with 
recombinant transglutaminase 2 and IgA using duodenal bulb biopsy sections from 
untreated coeliac disease (CD)-patients 1–4 (A–D), non-CD controls 1–3 (E–G), and a 
secondary control (H). A single double positive cell was detected in three untreated CD-
patient sections (A–C). Recombinant transglutaminase 2 (rTG2) is shown in red, IgA in 
green, DAPI in blue, and co-localization in yellow. Double positive cells are marked with an 
arrow in the enlarged images. Images were acquired using Olympus IX51 microscope with 
magnification ×20. The original image is shown in the top-right corner and the white 
rectangle represents the area of the enlarged image. Scale bar = 100 μm. 
The presence of early phase TG2-specific B cells that had yet to undergo CSR was 
investigated using combinations rTG2-IgD and rTG2-IgM. Four cells with rTG2-IgD co-
localization were detected in two untreated CD-patient sections, two double positive cells in 
each. One rTG2-IgD double positive cell was detected in a non-CD control. All of the rTG2-
IgD double positive cells were located in the villus layer. Few IgD single positive cells were 
detected in all specimens. A small IgD single positive cell cluster was detected in one 
untreated CD-patient section and in one non-CD control section. No rTG2-IgM double 
positive cells were detected in untreated CD-patient sections. One double positive cell located 
in the neck of a villus was detected in one non-CD control. Few dispersedly localized IgM 
single positive cells were detected in all sections, although the number was higher in 
untreated CD-patients. Results of rTG2-IgD and rTG2-IgM combinations are presented in 
Figure 13 and Figure 14. 
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Figure 13. Representative images of immunofluorescence double staining with 
recombinant transglutaminase 2 and IgD using duodenal bulb biopsy sections from 
untreated coeliac disease (CD)-patients 1–4 (A–D), non-CD controls 1–3 (E–G), and a 
secondary control (H). A total of four double positive cells were detected in two untreated 
CD-patient sections (B, D) and one double positive cell in one untreated CD-patient section 
(E). A small cluster of IgD single positive cells was detected in one untreated CD-patient 
section (A) and in one non-CD control section (F). Recombinant transglutaminase 2 (rTG2) is 
shown in red, IgD in green, DAPI in blue, and co-localization in yellow. Double positive cells 
are marked with an arrow in the enlarged images. Images were acquired using Olympus IX51 
microscope with magnification ×20. The original image is shown in the top-right corner and 
the white rectangle represents the area of the enlarged image. Scale bar = 100 μm. 
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Figure 14. Representative images of immunofluorescence double staining with 
recombinant transglutaminase 2 and IgM using duodenal bulb biopsy sections from 
untreated coeliac disease (CD)-patients 1–4 (A–D), non-CD controls 1–3 (E–G), and a 
secondary control (H). One double positive cell was detected in a non-CD control section 
(G). Recombinant transglutaminase 2 (rTG2) is shown in red, IgM in green, DAPI in blue, 
and co-localization in yellow. The double positive cell is marked with an arrow in the 
enlarged image. Images were acquired using Olympus IX51 microscope with magnification 
×20. The original image is shown in the top-right corner and the white rectangle represents 
the area of the enlarged image. Scale bar = 100 μm. 
 
The presence of TG2-specific B cells with ongoing CSR was investigated using rTG2-AID 
co-localization. Altogether four cells with rTG2-AID co-localization were detected in three 
untreated CD-patient sections. One section contained two double positive cells and two 
sections contained a single double positive cell. One of such cells was located in a villus and 
the three other cells were located in the neck of a villus or close to the intestinal epithelium. 
No co-localizations were detected in non-CD controls. Few AID single positive cells were 
detected in all sections. Results are presented in Figure 15. 
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Figure 15. Representative images of immunofluorescence double staining with 
recombinant transglutaminase 2 and activation-induced cytidine deaminase (AID) using 
duodenal bulb biopsy sections from untreated coeliac disease (CD)-patients 1–4 (A–D), 
non-CD controls 1–3 (E–G), and a secondary control (H). A total of four double positive 
cells were detected in three untreated CD-patient sections (B–D). Recombinant 
transglutaminase 2 (rTG2) is shown in red, AID in green, DAPI in blue, and co-localization in 
yellow. Double positive cells are marked with an arrow in the enlarged images. Images were 
acquired using Olympus IX51 microscope with magnification ×20. The original image is 
shown in the top-right corner and the white rectangle represents the area of the enlarged 
image. Scale bar = 100 μm.  
 
The presence of TG2-specific B cells that had not yet matured into plasma cells was 
investigated using rTG2-Pax5 combination. No cells with rTG2-Pax5 co-localization were 
detected in untreated CD-patients. One double positive cell located in the neck of a villus was 
detected in two non-CD control sections. A low number of dispersedly localized Pax5 single 
positive cells were detected in all sections. Results are presented in Figure 16. 
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Figure 16. Representative images of immunofluorescence double staining with 
recombinant transglutaminase 2 and Pax5 using duodenal bulb biopsy sections from 
untreated coeliac disease (CD)-patients 1–4 (A–D), non-CD controls 1–3 (E–G), and a 
secondary control (H). A single double positive cell was detected in two non-CD control 
sections (E, G). Recombinant transglutaminase 2 (rTG2) is shown in red, Pax5 in green, 
DAPI in blue, and co-localization in yellow. Double positive cells are marked with an arrow 
in the enlarged images. Images were acquired using Olympus IX51 microscope with 
magnification ×20. The original image is shown in the top-right corner and the white 
rectangle represents the area of the enlarged image. Scale bar = 100 μm. 
 
After the TG2-specific co-localizations, IgA-AID combination was used to detect all IgA 
positive B cells that were undergoing CSR to identify potential lymphoid follicle structures. A 
single IgA-AID double positive cell was detected in two untreated CD-patient sections and in 
one non-CD control section. All three double positive cells were located in villi. A high 
amount of dispersedly localized IgA single positive cells and a low number of dispersedly 
localized AID single positive cells were detected in all sections. Results are presented in 
Figure 17. 
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Figure 17. Representative images of immunofluorescence double staining with IgA and 
activation-induced cytidine deaminase (AID) using duodenal bulb biopsy sections from 
untreated coeliac disease (CD)-patients 1–4 (A–D), non-CD controls 1–3 (E–G), and a 
secondary control (H). One double positive cell was detected in two untreated CD-patient 
sections (B, D) and in one non-CD control section (E). IgA is shown in red, AID in green, 
DAPI in blue, and co-localization in yellow. Double positive cells are marked with an arrow 
in the enlarged images. Images were acquired using Olympus IX51 microscope with 
magnification ×20. The original image is shown in the top-right corner and the white 
rectangle represents the area of the enlarged image. Scale bar = 100 μm.  
 
The presence of all IgA positive B cells before maturation into plasma cells was detected 
using IgA-Pax5 combination. Multiple double positive cells were detected in all untreated 
CD-patient sections and in two non-CD control sections. Most of the double positive cells 
were in small clusters located in villi or close to the intestinal epithelium. The number of 
dispersedly localized IgA single positive cells was high in all sections, and a low amount of 
dispersedly localized Pax5 positive cells was detected as well. Results are presented in Figure 
18. 
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Figure 18. Representative images of immunofluorescence double staining with IgA and 
Pax5 using duodenal bulb biopsy sections from untreated coeliac disease (CD)-patients 
1–4 (A–D), non-CD controls 1–3 (E–G), and a secondary control (H). Double positive 
cells were detected in all untreated CD-patient sections (A–D) and in two non-CD control 
sections (E, G). IgA is shown in red, Pax5 in green, DAPI in blue, and co-localization in 
yellow. Double positive cells are marked with an arrow in the enlarged images. Images were 
acquired using Olympus IX51 microscope with magnification ×20. The original image is 
shown in the top-right corner and the white rectangle represents the area of the enlarged 
image. Scale bar = 100 μm.  
 
The presence of all B cells that were undergoing CSR in potential lymphoid follicle structures 
was investigated using IgD-AID combination. A total of six double positive cells were 
detected in three untreated CD-patient sections and a total of three double positive cells in two 
non-CD control sections. All double positive cells were located close to the intestinal 
epithelium. Few dispersedly localized IgD and AID single positive cells were detected in all 
sections. Results are presented in Figure 19. 
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Figure 19. Representative images of immunofluorescence double staining with IgD and 
activation-induced cytidine deaminase (AID) using duodenal bulb biopsy sections from 
untreated coeliac disease (CD)-patients 1–4 (A–D), non-CD controls 1–3 (E–G), and a 
secondary control (H). Double positive cells were detected in three untreated CD-patient 
sections (B–D) and in two non-CD control sections (F–G). IgD is shown in green, AID in red, 
DAPI in blue, and co-localization in yellow. Double positive cells are marked with an arrow 
in the enlarged images. Images were acquired using Olympus IX51 microscope with 
magnification ×20. The original image is shown in the top-right corner and the white 
rectangle represents the area of the enlarged image. Scale bar = 100 μm. 
 
Finally, the presence of all early phase B cells was investigated using IgD-Pax5 combination. 
A total of six double positive cells were detected in three untreated CD-patient sections and a 
total of five double positive cells in all non-CD control sections. One potential double positive 
cell cluster was detected in one untreated CD-patient section and in one non-CD control 
section. All double positive cells were located close to the intestinal epithelium. A low 
number of dispersedly localized IgA and Pax5 single positive cells were detected in all 
sections. Results are presented in Figure 20. 
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Figure 20. Representative images of immunofluorescence double staining with IgD and 
Pax5 using duodenal bulb biopsy sections from untreated coeliac disease (CD)-patients 
1–4 (A–D), non-CD controls 1–3 (E–G), and a secondary control (H). Double positive 
cells were detected in three untreated CD-patient sections (A–C) and in all non-CD control 
sections (E–G). One potential double positive cell cluster was detected in an untreated CD-
patient section (A) and in a non-CD control section (F). IgD is shown in red, Pax5 in green, 
DAPI in blue, and co-localization in yellow. Double positive cells are marked with an arrow 
in the enlarged images. Images were acquired using Olympus IX51 microscope with 
magnification ×20. The original image is shown in the top-right corner and the white 
rectangle represents the area of the enlarged image. Scale bar = 100 μm. 
 
When comparing all results, rTG2 appeared to be most co-localized with AID. The expression 
of IgA and IgD single positive cells was more abundant compared to Pax5 and AID single 
positive cells, and the number of IgA, IgM, and IgD single positive B cells was higher than 
the number of TG2-specific B cells of the specific Ig class. The number of positive untreated 
CD-patients and non-CD controls for each combination is summarized in Table 6. 
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Table 6. Results of the immunofluorescence double staining combinations. Target of the 
co-localization and the amount of positive untreated coeliac disease (CD)-patients and non-
CD controls are described for each combination. 
Combination Target CD-patients Controls 
rTG2-IgA Mature naïve TG2-specific B cells, plasmablasts or 
plasma cells 
3/4 Negative 
rTG2-IgD Early phase TG2-specific B cells before class-switch 2/4 1/3 
rTG2-IgM Early phase TG2-specific B cells before class-switch Negative 1/3 
rTG2-AID TG2-specific B cells with ongoing IgA class-switch 3/4 Negative 
rTG2-Pax5 TG2-specific B cells before transition into plasma cells Negative 2/3 
IgA-AID B cells with ongoing IgA class-switch 2/4 1/3 
IgA-Pax5 IgA-specific B cells before transition into plasma cells 4/4 2/3 
IgD-AID B cells with ongoing class-switch 3/4 2/3 
IgD-Pax5 Early phase B cells 3/4 3/3 
AID: activation-induced cytidine deaminase; rTG2: recombinant transglutaminase 2 
 
Despite the few positive cell clusters detected in the stained sections, only one structure was 
detected in one untreated CD-patient that resembled the potential lymphoid tissue in the 
screened section stained for TCRγδ+ T cells using immunohistochemistry, which is shown in 
Figure 21. The structure contained a circular zone of IgD positive B cells. No co-localization 
with Pax5 or rTG2 was detected in the structure. 
 
 
Figure 21. Potential lymphoid structure in an untreated CD-patient duodenal bulb 
biopsy section. All three images are from the same location of untreated CD-patient 2. (A) 
IgD-Pax5 combination using immunofluorescence staining. IgD is shown in red and Pax5 in 
green. (B) IgD-recombinant transglutaminase 2 (rTG2) combination using 
immunofluorescence staining. IgD is shown in green and rTG2 in red. (C) T cell receptor 
(TCR)-γδ positive T cells stained using immunohistochemistry. DAPI is shown in blue in all 
images. No Pax5 or TG2 positive cells were detected in the double stained sections (A–B). 
Immunofluorescence images (A–B) were acquired using Olympus IX51 microscope and the 
brightfield image (C) using Olympus BX60 with magnification ×10. Scale bar = 200 μm.  
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6 Discussion 
This study aimed to investigate the location of early phase TG2-specific B cells in the 
duodenal bulb of CD-patients using immunofluorescence staining and co-localization with 
rTG2 against IgD, IgM, IgA, AID, and Pax5. The amount of studies on the early development 
of human TG2-specific B cells has been minimal, as most of the research material consists of 
either isolated cells from the small intestine (Spencer and Sollid 2016) or diagnostic biopsies 
from the duodenum and jejunum of CD-patients, which are devoid of lymphoid tissues that 
contain sites for B cell development. Furthermore, several studies on lymphoid tissues, 
particularly ILFs, are based on mice or other species (Hamada et al. 2002; Nochi et al. 2013; 
Pabst et al. 2005; Tsuji et al. 2008; Wang et al. 2006). There are fundamental differences that 
exist between species, which prevents extrapolation from mice to humans (Spencer and Sollid 
2016). In addition, the TG2-specific B cell response has not been studied in mice. Therefore, 
comparing the results of this study with previous studies was difficult. Nonetheless, the 
gained results raised speculations and hypotheses, which I will discuss next. 
6.1 Identification of lymphoid tissues in duodenal bulb biopsies 
This study comprised 479 cryosected duodenal bulb biopsies from untreated CD-patients and 
non-CD individuals. The high amount of material was to ensure that there were enough high-
quality specimens with potential lymphoid structures. Cryosections were used due to better 
preservation of the epitopes compared to histological methods that include fixation with 
formalin (Son et al. 2013). However, cryosections also have a weaker morphology compared 
to formalin-fixed specimens (Son et al. 2013). 
Considering the high amount of starting material, the number of screened specimens that 
contained potential lymphoid structures was low. This is explained by the lack of 
recognizable structures and the varying morphology of the duodenal bulb biopsies (Lindfors 
et al. 2019; Taavela et al. 2016). The potential abnormal histological findings in the duodenal 
bulb biopsies may explain the difficulty in recognizing potential lymphoid structures (Stoven 
et al. 2016; Taavela et al. 2016). In addition, many of the Romanian duodenal bulb biopsies 
had been collected from individuals with various infections, which increased the risk of the 
specimens containing non-CD-specific lymphoid structures. Because of this, only one 
Romanian untreated CD-patient and one non-CD control without any apparent infection were 
included in the final staining. 
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As for the number of the potential lymphoid structures, the amount of detected ILFs and 
diffuse lymphoid tissue was the highest, whereas the number of PPs was the lowest. This is 
explained by the distinct structure of the PPs with high specificity, whereas ILFs and diffuse 
lymphoid tissue lack a distinct shape, and therefore the potential ILF and lymphoid tissue 
structures may include non-specific cell aggregates. 
6.2 Identification of transglutaminase 2-specific B cells in duodenal bulb 
High-quality duodenal bulb biopsy specimens from four untreated CD-patients and three non-
CD controls were selected for the immunofluorescence double staining. Using rTG2, it was 
possibly to visualize TG2-specific B cells and plasma cells in the sections (Di Niro et al. 
2016). In addition, early phase TG2-specific B cells were detected using co-localization with 
antibodies specifically targeting IgA, IgD, IgM, AID, and Pax5. To confirm the potential 
lymphoid structures that were detected during the screening, a double staining with IgA and 
IgD combined with AID and Pax5 was performed. 
A low amount of IgA positive TG2-specific cells was detected in three out of four untreated 
CD-patient sections. These cells could be either late phase TG2-specific B cells, plasmablasts, 
or plasma cells. All double positive cells were found in the apical area of the mucosa in 
proximity of the lumen, where TG2-specific plasma cells are generally localized (Di Niro et 
al. 2016). Therefore, it is a high possibility that the detected cells were plasma cells, which 
suggests that TG2-specific plasma cells may localize to the duodenal bulb mucosa. This could 
be confirmed by using a co-localization with rTG2 and an anti-CD138 antibody, which is 
used to detect plasma cells (Di Niro et al. 2016). No double positive cells were observed in 
untreated CD-patient 4. A possible explanation could be that the double positive cells were 
located in other sections of the biopsy specimen. On the other hand, no diagnosed data was 
provided for the patient, and therefore the patient could possibly be negative for CD-specific 
IgA antibodies. In parallel to the studies by Di Niro and co-workers, and Hietikko and co-
workers using small-intestinal biopsies, no TG2-IgA double positive cells were found in the 
non-CD control duodenal bulb biopsy specimens (Di Niro et al. 2016; Hietikko et al. 2018). 
Few rTG2-IgD co-localizations were detected in two untreated CD-patients, which suggests 
that TG2-specific B cells that have yet to undergo CSR may exist in the duodenal bulb. All 
double positive cells were found in the villus layer in proximity of the lumen. As majority of 
the lymphoid tissues have been found to be located further in the LP, including PPs and ILFs 
in mice (Knoop and Newberry 2012; Lorenz and Newberry 2004), this could suggest that the 
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cells were not part of any lymphoid structure. This is further supported by the fact that the 
double positive cells were not surrounded by other IgD single positive B cells as in lymphoid 
follicles (Buettner and Lochner 2016). 
Despite the few detected IgD positive TG2-specific cells, no rTG2-Pax5 co-localizations were 
detected in the untreated CD-patient sections. This is puzzling, as the expression of Pax5 is 
associated with developing B cell lineages (Medvedovic et al. 2011; Rothenberg 2014). 
Considering the three-dimensional structure of the GALT and the two-dimensional biopsy 
sections, it is possible that the identified IgD positive and TG2-specific B cells were detected 
in a different layer than in the sections that were stained using anti-Pax5 antibody. This is 
supported by the fact that a low amount of Pax5 single positive cells was detected in the 
sections parallel to IgD single positive cells.  
No rTG2-IgM co-localizations were detected in the untreated CD-patient sections. This could 
be explained by the fact that in mice, most GALT B cells express phenotype IgD
high
IgM
low 
(Hamada et al. 2002), and therefore the number of IgM positive cells could be low and 
possibly located in other layers that were not stained. Overall, the amount of IgD and IgM 
positive B cells was low in all sections, which suggests that the number of early phase B cells 
in the duodenal bulb may be low. 
Few rTG2-AID co-localizations were detected in three out of four untreated CD-patient 
sections. As AID is associated with CSR that mostly occurs in germinal centers of lymphoid 
follicles, the location of the double positive cells may give a hint whether the TG2-specific B 
cells develop in lymphoid follicles or at extra-follicular sites (Dominguez-Sola and Cattoretti 
2017; He et al. 2007). All double positive cells were detected in the villus layer without any 
recognizable forms of cell aggregations, which was in parallel to the rTG2-IgD co-
localizations. Therefore, the results would again suggest that the development of TG2-specific 
B cells may occur at extra-follicular sites of the duodenal bulb mucosa. Of note, the results 
seem to conflict with the study by Di Niro and co-workers, in which they did not detect AID 
in TG2 positive plasmablasts of the small intestine and suggested that TG2-specific B cells 
may undergo CSR outside the small-intestinal mucosa, although their study may not be 
comparable with this study as they used a different method (Di Niro et al. 2012). 
Overall, the number of TG2-specific B cells was significantly higher in untreated CD-patients 
than in non-CD controls. Interestingly, few rTG2-IgD, rTG2-IgM, and rTG2-Pax5 co-
localizations were detected in non-CD controls 1 and 3. The possibility of an error during the 
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staining is unlikely, as the specimens were positive in multiple staining combinations. The 
EmA dilution of 1:5 from the serum sample of the non-CD control 1 could indicate a potential 
early phase CD. Non-CD control 3 was a Romanian child without a diagnosed CD, but no 
further data was provided. Therefore, the individual could have a potential early phase CD as 
well or an infection that could affect the results. On the other hand, the fact that no rTG2-IgA 
double positive cells were detected in the non-CD controls could suggest that early phase 
TG2-specific cells expressing IgD and IgM could develop in non-CD individuals, but the 
immune system induces the apoptosis of these cells before they undergo CSR. Nonetheless, 
using control specimens from fully healthy individuals with all diagnosed data available in 
further studies would possibly prevent similar results.  
Additional co-localizations using IgA and IgD combined with AID and Pax were used to 
detect all B cells to identify possible lymphoid structures in the sections. As expected, the 
amount of double positive cells was higher in all combinations compared to the rTG2 co-
localizations. Particularly, the number of IgA single positive cells was high in all sections, 
suggesting that a high number of IgA positive B cells, plasmablasts, and plasma cells 
targeting other antigens than TG2 could exist in the duodenal bulb. 
Few IgD single positive cell aggregates were identified close to the intestinal epithelium or at 
the base of crypts, which could indicate potential ILF structures. However, no recognizable 
structures were found at the sites of the rTG2 co-localizations. When comparing to the 
potential lymphoid structures that were identified during the screening, only one similar 
structure was found in one untreated CD-patient. The structure consisted of a circular zone of 
IgD positive cells and an inner zone that contained no IgD positive cells. According to Iversen 
and co-workers, germinal centers are surrounded by a zone of IgD positive cells, but there are 
no IgD positive cells within the germinal center (Iversen et al. 2015). Therefore, the structure 
could be identified as a germinal center of a potential ILF. No TG2-specific cells were 
detected in the structure, which suggests that the germinal center has formed in response to a 
different antigen. Interestingly, no Pax5 positive cells were detected in the structure, which 
seems to parallel the results of rTG2-Pax5 co-localization. 
All in all, the results suggest that a low number of developing TG2-specific B cells may exist 
in the duodenal bulb and at extra-follicular sites, which supports the hypothesis. However, the 
limitations of this study must be taken into consideration before accepting with all the results. 
First, the use of antibodies as detection tools in GALT has been considered challenging due to 
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the presence of similar molecules and antibody receptors expressed in cell populations within 
GALT (Dominguez-Sola and Cattoretti 2017). Second, interpolating a three-dimensional 
structure from two-dimensional data is difficult, particularly when the precise structural data 
is crucial to fully understand the function of the lymphatic networks in the GALT. Finally, the 
cryosected sections provide a temporally limited view on the analysis of cell dynamics during 
the development in GALT. 
6.3 Future aspects 
The high amount of starting material provided a sufficient number of high-quality specimens 
for this study. However, considering the limitations of the two-dimensional data provided by 
the cut sections, more specimens could be included in further investigations, including 
specimens from individuals with different ages. Furthermore, additional staining 
combinations could be used to confirm the different developmental stages of the B cells, 
including Ki-67 to detect proliferating plasmablasts and CD138 to detect plasma cells. Triple 
staining combinations, such as rTG2-IgD-CD19, could be used to identify B cells at different 
stages with high accuracy. A triple staining using rTG2-AID with IgA or IgD would make it 
possible to identify the Ig class of the AID positive cells. Considering the lack of recognizable 
lymphoid structures in this study, there was no need to identify different lymphoid tissue 
types. However, if a need would arise in further studies, antibodies against CD11c expressed 
on FAE DCs could be used to identify ILFs and PPs from diffuse lymphoid tissue. Lastly, 
confocal microscopy could be included to confirm the co-localization of the epitopes, 
particularly combinations with rTG2.  
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7 Conclusions 
A recent hypothesis suggests that the development of CD-patient TG2-specific B cells may 
occur outside lymphoid follicles. Therefore, this study aimed to identify the location of early 
phase TG2-specific B cells in the duodenal bulb, which is known to contain a high number of 
lymphoid tissues with lymphoid follicles. This was achieved by studying prospectively 
collected cohorts, which included cryosected duodenal bulb biopsy specimens from Finnish 
and Romanian CD-patients and healthy individuals. The cohorts are unique, as they represent 
the largest collection of frozen human duodenal bulb biopsies to study the development of 
CD-specific B cells in this specific location. The biopsy specimens were screened, and seven 
high-quality specimens were selected for immunofluorescence double staining to detect TG2-
specific B cells and lymphoid structures. 
A low amount of TG2-specific B cells expressing IgD or AID was detected in the CD-patient 
biopsy sections. However, the double positive cells did not appear to form recognizable 
follicle-like cell clusters or be located in areas which would typically contain lymphoid 
tissues with lymphoid follicles. Both IgD and AID are associated with early phase B cells. In 
addition, AID has been associated with CSR that commonly occurs in lymphoid follicles 
which contain aggregates of B cells. Therefore, the results suggest that developing TG2-
specific B cells may exist in the duodenal bulb and that the development may take place in the 
mucosa outside lymphoid follicles, as the hypothesis suggests. Interestingly, TG2-specific B 
cells expressing Pax5 were only detected in two non-CD controls but not in the CD-patients, 
even though Pax5 is assumed to be expressed in all developing B cells. This could suggest 
that the amount of developing TG2-specific B cells in the duodenal bulb is very low. 
Further studies on the development of TG2-specific B cells can be based on this knowledge 
that a low amount of early phase TG2-targeting B cells may exist in the duodenal bulb 
mucosa. More research on the early development of TG2-targeting B cells can help to 
understand the exact mechanism how CD is activated, and therefore help in discovering new 
treatment options. 
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